<template lang="html">
  <section class="POLYARTHRITE_RHUMATOIDE">
    <h2 class="title">POLYARTHRITE RHUMATOÏDE</h2>
<span class="line"></span>

    <p>
      - PR auto-immune : Rituximab, Abatacept
      <br>
      - PR inflammatoire : anti-IL6, anti-TNF, anti-JAK
    </p>

    <table>
      <tr>
        <th></th>
        <th>Polyarthrite Rhumatoïde</th>
        <th>Rhumatisme psoriasique</th>
        <th>Psoriasis</th>
      </tr>

      <tr>
        <td>
          Anti–TNF<br>
          Infliximab<br>
          Adalimumab<br>
          Etanercept<br>
          Golimumab<br>
          Certolizumab<br>
        </td>
        <td class="green"></td>
        <td class="green"></td>
        <td class="green">Tous sauf Golimumab</td>
      </tr>

      <tr>
        <td>
          Anti IL-6 R<br>
          Tocilizumab<br>
          Sarilumab<br>
        </td>
        <td class="green"></td>
        <td rowspan="2" colspan="2"  class="red">
          Efficace dans les données préliminaires
          <br><br>
          Peu de données d’efficacité
        </td>
      </tr>

      <tr>
        <td>
          Anti IL-1<br>
          Anakinra<br>
        </td>
        <td  class="green"></td>
      </tr>

      <tr>
        <td>
          Anti IL-12/23<br>
          Ustekinumab<br>
        </td>
        <td class="red">CJP non atteint dans les essais</td>
        <td class="green"></td>
        <td class="green"></td>
      </tr>

      <tr>
        <td>
          Anti IL-23<br>
          Guselkumab
        </td>
        <td class="red">CJP non atteint dans les essais</td>
        <td class="orange">Efficace dans les données préliminaires</td>
        <td class="green"></td>
      </tr>

      <tr>
        <td>
          Anti IL-17<br>
          Ixekizumab (17A/F)<br>
          Secukinumab (17A)
        </td>
        <td class="red">CJP non atteint dans les essais</td>
        <td class="green"></td>
        <td class="green"></td>
      </tr>

      <tr>
        <td>
          Anti IL-17 Récepteur<br>
          Brodalumab (17A/F)<br>
        </td>
        <td class="red"></td>
        <td class="red"></td>
        <td class="green"></td>
      </tr>
      <tr>
        <td>
          Anti JAK<br>
          Tofacitinib<br>
          Baricitinib<br>
          Upadacitinib
        </td>
        <td class="green"></td>
        <td class="green">Que Tofacitinib</td>
        <td class="red">Efficace dans les données préliminaires</td>
      </tr>

      <tr>
        <td>Anti CD-20<br>
          Rituximab
        </td>
        <td class="green"></td>
        <td colspan="2" class="red">CJP non atteint dans les essais</td>
      </tr>

      <tr>
        <td>PDE4<br>
          Apremilast
        </td>
        <td class="red"></td>
        <td class="green"></td>
        <td class="green"></td>
      </tr>

      <tr>
        <td>Abatacept</td>
        <td class="green"></td>
        <td class="green">Non remboursé</td>
        <td class="red"></td>
      </tr>

      <tr>
        <td></td>
        <td class="green">Spondyloarthrite axiale radiographique</td>
        <td class="green">Spondyloarthrite axiale non radiographique</td>
        <td class="red">MICI</td>
      </tr>

      <tr>
        <td>Anti–TNF<br>
          Infliximab<br>
          Adalimumab<br>
          Etanercept
        </td>
        <td class="green">Tous</td>
        <td class="green">Tous sauf Infliximab</td>
        <td class="red">Crohn : IFX et Adalimumab</td>
      </tr>

      <tr>
        <td>Golimumab<br>
          Certolizumab
        </td>
        <td class="green"></td>
        <td class="green"></td>
        <td class="red">RCUH : IFX, adalimumab et Golimumab</td>
      </tr>

      <tr>
        <td>Anti IL-6 R<br>
          Tocilizumab<br>
          Sarilumab
        </td>
        <td class="green"></td>
        <td class="green"></td>
        <td class="red"></td>
      </tr>

      <tr>
        <td>Anti IL-1<br>
          Anakinra
        </td>
        <td class="green"></td>
        <td class="green"></td>
        <td class="red"></td>
      </tr>

      <tr>
        <td>Anti IL-12/23<br>
          Ustekinumab
        </td>
        <td class="green"></td>
        <td class="green"></td>
        <td class="red">Pour Crohn uniquement</td>
      </tr>

      <tr>
        <td>Anti IL-23<br>
          Guselkumab
        </td>
        <td class="green"></td>
        <td class="green"></td>
        <td class="red">Efficace dans les données préliminaires</td>
      </tr>

      <tr>
        <td>Anti IL-17<br>
          Ixekizumab (17A/F)<br>
          Secukinumab (17A)
        </td>
        <td class="green"></td>
        <td class="green"></td>
        <td class="red">Peut aggraver les MICI</td>
      </tr>

      <tr>
        <td>Anti IL-17 Récepteur<br>
          Brodalumab (17A/F)
        </td>
        <td class="green"></td>
        <td class="green"></td>
        <td class="red"></td>
      </tr>

      <tr>
        <td>Anti JAK<br>
          Tofacitinib<br>
          Baricitinib<br>
          Upadacitinib
        </td>
        <td class="green">Efficace dans les données préliminaires</td>
        <td class="green"></td>
        <td class="red">Que Tofa pour RCUH uniqumement</td>
      </tr>

      <tr>
        <td>Anti CD-20<br>
          Rituximab
        </td>
        <td class="green">CJP non atteint dans les essais</td>
        <td class="green"></td>
        <td class="red"></td>
      </tr>

      <tr>
        <td>PDE4<br>
          Apremilast
        </td>
        <td class="green">CJP non atteint dans les essais</td>
        <td class="green"></td>
        <td class="red"></td>
      </tr>
    </table>
  </section>
</template>

<script lang="js">
    export default {
        name: 'POLYARTHRITE_RHUMATOIDE',
        props: [],
        mounted() {},
        data() {
            return {};
        },
        methods: {},
        computed: {}
    }
</script>

<style scoped lang="scss">
@import "src/sass/global.scss";
    .POLYARTHRITE_RHUMATOIDE {
      padding: 0 15px;
      text-align: left;



      .bold {
        font-weight: bold;
      }

      .underline {
        text-decoration: underline;
      }

      table {
        border-collapse: collapse;
        width: 100%;
        margin-bottom: 15px;
      }

      td, th {
        border: 1px solid black;
        padding: 8px;
        vertical-align: baseline;

        &.sep {
          color: indianred;
          font-weight: bold;
          text-align: center;
        }
      }

      table tr:nth-child(even){background-color: #cfd5ea;}
      table tr:nth-child(odd){background-color: #e9ebf5;}

      td.green {
        background-color: #92d050;
      }

      td.red {
        background-color: #ff0000;
      }

      td.orange {
        background-color: #ffe699;
      }

      table th {
        padding-top: 12px;
        padding-bottom: 12px;
        text-align: left;
        background-color: #4472c4;
        color: black;
      }
    }
</style>
